ALKS - Alkermes plc
NASDAQ
->
Healthcare
->
Biotechnology
Dublin,
Ireland
Type: Equity
ALKS price evolution
ALKS
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $457.47 | $647.71 | $665.79 | $321.4 |
| Short term investments | $316.02 | $241.44 | $163.25 | $279.06 |
| Net receivables | $332.48 | $337.7 | $334.48 | $269.18 |
| Inventory | $186.41 | $192.19 | $189.37 | $184.98 |
| Total current assets | $1485.51 | $1464.78 | $1397.35 | $1110.06 |
| Long term investments | $39.89 | $106.43 | $78.13 | $92.08 |
| Property, plant & equipment | $318.4 | $430.69 | $431.16 | $432.69 |
| Goodwill & intangible assets | $85.02 | $103.86 | $112.86 | $121.75 |
| Total noncurrent assets | $650.72 | $814.45 | $789.83 | $812.67 |
| Total investments | $355.91 | $347.87 | $241.38 | $371.14 |
| Total assets | $2136.22 | $2279.23 | $2187.18 | $1922.73 |
| Current liabilities | ||||
| Accounts payable | $240.56 | $243.26 | $242.92 | $190.15 |
| Deferred revenue | ||||
| Short long term debt | $8.75 | $18.06 | $18.19 | $18.3 |
| Total current liabilities | $520.22 | $503.11 | $487.19 | $492.91 |
| Long term debt | $363.44 | $366.92 | $371.34 | $375.75 |
| Total noncurrent liabilities | $413.32 | $420.54 | $419.56 | $424.24 |
| Total debt | $372.19 | $384.98 | $389.54 | $394.05 |
| Total liabilities | $933.54 | $923.65 | $906.75 | $917.15 |
| Shareholders' equity | ||||
| Retained earnings | -$1343.53 | -$1456.31 | -$1504.07 | -$1741.13 |
| Other shareholder equity | -$3.11 | -$6.07 | -$7.44 | -$8.13 |
| Total shareholder equity | $1202.69 | $1355.58 | $1280.44 | $1005.58 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $457.47 | $292.47 | $337.54 | $272.96 |
| Short term investments | $316.02 | $315.99 | $198.77 | $362.07 |
| Net receivables | $332.48 | $296.9 | $313.19 | $275.14 |
| Inventory | $186.41 | $181.42 | $150.34 | $125.74 |
| Total current assets | $1485.51 | $1130.31 | $1062.17 | $1110.97 |
| Long term investments | $39.89 | $131.61 | $229.43 | $24.78 |
| Property, plant & equipment | $318.4 | $441.22 | $456.68 | $481.72 |
| Goodwill & intangible assets | $85.02 | $130.55 | $166.92 | $204.06 |
| Total noncurrent assets | $650.72 | $833.67 | $962.32 | $838.76 |
| Total investments | $355.91 | $447.6 | $428.2 | $386.85 |
| Total assets | $2136.22 | $1963.98 | $2024.48 | $1949.73 |
| Current liabilities | ||||
| Accounts payable | $240.56 | $32.84 | $445.71 | $412.17 |
| Deferred revenue | $7.51 | |||
| Short long term debt | $8.75 | $18.72 | $19.24 | $18.57 |
| Total current liabilities | $520.22 | $497.74 | $471.29 | $438.26 |
| Long term debt | $363.44 | $290.27 | $396.97 | $391.58 |
| Total noncurrent liabilities | $413.32 | $422.48 | $440.61 | $444.49 |
| Total debt | $372.19 | $398.82 | $416.21 | $410.16 |
| Total liabilities | $933.54 | $920.23 | $911.9 | $882.75 |
| Shareholders' equity | ||||
| Retained earnings | -$1343.53 | -$1699.29 | -$1541.02 | -$1492.85 |
| Other shareholder equity | -$3.11 | -$10.89 | -$3.72 | -$1.35 |
| Total shareholder equity | $1202.69 | $1043.75 | $1112.58 | $1066.98 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $377.48 | $380.94 | $617.4 | $287.6 |
| Cost of revenue | $70.09 | $61.51 | $63.26 | $58.17 |
| Gross Profit | $307.38 | $319.43 | $554.14 | $229.42 |
| Operating activities | ||||
| Research & development | -$20.76 | $97.14 | $100.79 | $93.64 |
| Selling, general & administrative | $140.57 | $169.45 | $205.26 | $174.48 |
| Total operating expenses | $128.81 | $275.58 | $314.94 | $276.91 |
| Operating income | $178.57 | $43.85 | $239.19 | -$47.49 |
| Income from continuing operations | ||||
| EBIT | $24.91 | $53.37 | $245.44 | -$42.57 |
| Income tax expense | -$93.92 | -$0.4 | $2.69 | -$6.01 |
| Interest expense | $6.05 | $6.01 | $5.68 | $5.29 |
| Net income | ||||
| Net income | $112.78 | $47.76 | $237.06 | -$41.84 |
| Income (for common shares) | $112.78 | $47.76 | $237.06 | -$41.84 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1663.4 | $1111.8 | $1173.75 | $1038.76 |
| Cost of revenue | $253.04 | $218.11 | $197.39 | $178.32 |
| Gross Profit | $1410.37 | $893.69 | $976.36 | $860.44 |
| Operating activities | ||||
| Research & development | $270.81 | $393.84 | $406.53 | $394.59 |
| Selling, general & administrative | $689.75 | $605.75 | $560.98 | $538.83 |
| Total operating expenses | $996.25 | $1035.95 | $1005.65 | $972.87 |
| Operating income | $414.12 | -$142.26 | -$29.29 | -$112.43 |
| Income from continuing operations | ||||
| EBIT | $281.15 | -$154.26 | -$28.09 | -$87.88 |
| Income tax expense | -$97.64 | -$9.04 | $8.86 | $14.32 |
| Interest expense | $23.03 | $13.04 | $11.22 | $8.66 |
| Net income | ||||
| Net income | $355.76 | -$158.27 | -$48.17 | -$110.86 |
| Income (for common shares) | $355.76 | -$158.27 | -$48.17 | -$110.86 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $112.78 | $47.76 | $237.06 | -$41.84 |
| Operating activities | ||||
| Depreciation | $18.54 | $18.66 | $19.01 | $18.71 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $25.84 | $23.91 | $28.5 | $22.64 |
| Total cash flows from operations | $107.24 | $99.71 | $215.71 | -$21.3 |
| Investing activities | ||||
| Capital expenditures | -$16.68 | -$14.45 | -$9.7 | -$6.86 |
| Investments | -$4.3 | -$104.91 | $130.55 | $79.71 |
| Total cash flows from investing | -$20.98 | -$119.36 | $120.85 | $72.85 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.65 | $3.11 | $9.13 | $2.87 |
| Net borrowings | -$0.75 | -$0.75 | -$0.75 | -$0.75 |
| Total cash flows from financing | -$276.5 | $1.57 | $7.84 | -$22.62 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$190.24 | -$18.08 | $344.39 | $28.93 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $355.76 | -$158.27 | -$48.17 | -$110.86 |
| Operating activities | ||||
| Depreciation | $74.93 | $77.86 | $78.65 | $81.85 |
| Business acquisitions & disposals | $1.76 | $7.94 | $6.64 | |
| Stock-based compensation | $100.91 | $94.25 | $87.62 | $90.16 |
| Total cash flows from operations | $401.35 | $21.04 | $101.72 | $82.84 |
| Investing activities | ||||
| Capital expenditures | -$47.69 | -$38.26 | -$27.73 | -$41.58 |
| Investments | $101.05 | -$28.04 | -$45.41 | $23.46 |
| Total cash flows from investing | $53.36 | -$64.54 | -$66.2 | -$11.48 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $16.76 | $19.63 | $25.32 | $8.37 |
| Net borrowings | -$3 | -$3 | $20.32 | -$2.84 |
| Total cash flows from financing | -$289.71 | -$1.57 | $29.07 | -$2.17 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $165 | -$45.07 | $64.58 | $69.19 |
News
Fundamentals
| Market cap | $3.97B |
|---|---|
| Enterprise value | $3.88B |
| Shares outstanding | 166.98M |
| Revenue | $1.66B |
|---|---|
| EBITDA | $356.08M |
| EBIT | $281.15M |
| Net Income | $355.76M |
| Revenue Q/Q | 23.89% |
| Revenue Y/Y | 49.61% |
| P/E ratio | 11.15 |
|---|---|
| EV/Sales | 2.33 |
| EV/EBITDA | 10.90 |
| EV/EBIT | 13.81 |
| P/S ratio | 2.39 |
| P/B ratio | 3.29 |
| Book/Share | 7.22 |
| Cash/Share | 2.74 |
| EPS | $2.13 |
|---|---|
| ROA | 16.69% |
| ROE | 29.38% |
| Debt/Equity | 0.78 |
|---|---|
| Net debt/EBITDA | 1.34 |
| Current ratio | 2.86 |
| Quick ratio | 2.50 |